Cerecor Inc Closes on Initial Tranche of US$32 Milion Series B Financing
Cerecor Inc. has, announced the closing of the first tranche of a $32 million Series B financing. Proceeds from the round will support the development of Cerecor’s lead product candidate CERC-301, a first-in-class, oral, selective NR2B inhibitor in Phase II development as a once-a-day adjunctive therapy for severe MDD (major depressive disorder) with a rapid onset of action, and its catechol-O-methyltransferase (COMT) inhibitor platform for various conditions characterized by impairment of executive function and working memory.
“This financing enables Cerecor to continue to advance our compounds in nervous system disorders, including completion of Phase II development of CERC-301, which has the potential to save lives for patients experiencing major depressive disorder with suicidal ideation. We are building on intravenous ketamine’s extensive clinical experience with a more selective and specific oral agent that has the potential for improved safety,” said Blake M. Paterson, MD, Cerecor co-founder and CEO. "We are honored to have an outstanding group of investors who share our vision and are providing the funding to enable us to move both CERC-301 and our COMT platform forward.”
"Cerecor is committed to developing neuroscience compounds that could truly make a difference in patients’ lives, and this financing brings together an international group of investors committed to advancing the Company's lead product candidate, CERC-301,” said Jim Barrett, General Partner of NEA. "In an early clinical study conducted at the NIMH, CERC-301 demonstrated its potential for rapid onset of antidepressant effect, which would address a key unmet need for patients with depression. The Company has made outstanding progress in the last twelve months on this program."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance